CN Patent

CN101472906A — 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5－ht3和5－ht1a活性的化合物的1－[2－(2,4－二甲基苯基硫烷基)－苯基]哌嗪

Assigned to H Lundbeck AS · Expires 2009-07-01 · 17y expired

What this patent protects

1－[2－(2，4－二甲基苯基硫烷基)苯基]哌嗪对SERT、5－HT3和5－HT1A表现出有效的活性，并且可以以原样用于治疗认知损伤患者、特别是抑郁患者。

USPTO Abstract

1－[2－(2，4－二甲基苯基硫烷基)苯基]哌嗪对SERT、5－HT3和5－HT1A表现出有效的活性，并且可以以原样用于治疗认知损伤患者、特别是抑郁患者。

Drugs covered by this patent

vortioxetine-hydrobromide (VORTIOXETINE HYDROBROMIDE)

Patent Metadata

Patent number: CN101472906A
Jurisdiction: CN
Classification: —
Expires: 2009-07-01
Drug substance claim: No
Drug product claim: No
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.